Compare
60 Degrees Pharmaceuticals, Inc. vs Dare Bioscience, Inc. vs Bespoke Extracts, Inc. vs China SXT Pharmaceuticals, Inc.
| Latest fiscal year | 60 Degrees Pharmaceuticals, Inc. SXTP | Dare Bioscience, Inc. DARE | Bespoke Extracts, Inc. BSPKLast annual report: year ended 2024-12-31 | China SXT Pharmaceuticals, Inc. SXTC |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2024-12-31 | 2026-03-31 |
| Revenue | $1.01M | $1.03M | $1.12M | $1.14M |
| Revenue growth (YoY) | +65.5% | n/m | +42.3% | -34.6% |
| Gross margin | 22.3% | 71.3% (computed) | 40.5% | 21.9% |
| Operating margin | -771.6% | n/m | -89.0% | -625.9% |
| Net margin | -732.5% | n/m | -92.8% | -545.2% |
| Net income | -$7.37M | -$13.40M | -$1.04M | -$6.21M |
| EPS (Diluted) | -$11.73 | -$1.20 | -$0.10 | -$9.13 |
| Operating cash flow | -$6.85M | -$9.90M | -$289.8K | -$4.02M |
| Free cash flow | -$6.99M | -$10.29M | -$889.8K | n/a |
| Cash & equivalents | $1.51M | $24.71M | n/a | $28.18M |
| Total assets | $5.37M | $32.47M | $359.1K | $34.75M |
| Total liabilities | $1.99M | $29.63M | $2.45M | $5.05M |
| Shareholders' equity | $3.46M | $2.84M | -$2.09M | $29.71M |
| Return on year-end equity | -212.7% | -471.4% | n/a | -20.9% |
| Shares outstanding | 1.16M | 14.50M | 11.15M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | 60 Degrees Pharmaceuticals, Inc. | Dare Bioscience, Inc. | Bespoke Extracts, Inc. | China SXT Pharmaceuticals, Inc. |
|---|---|---|---|---|
| Latest | $1.01M Ended 2025-12-31 | $1.03M Ended 2025-12-31 | $1.12M Ended 2024-12-31 | $1.14M Ended 2026-03-31 |
| 1 year earlier | $607.6K Ended 2024-12-31 | $9.8K Ended 2024-12-31 | $785.5K Ended 2023-12-31 | $1.74M Ended 2025-03-31 |
| 2 years earlier | $253.6K Ended 2023-12-31 | $2.81M Ended 2023-12-31 | $3.4K Ended 2022-12-31 | $1.93M Ended 2024-03-31 |
| 3 years earlier | $223.2K Ended 2022-12-31 | $10.00M Ended 2022-12-31 | n/a | $1.97M Ended 2023-03-31 |
| 4 years earlier | n/a | $0 Ended 2021-12-31 | n/a | $2.60M Ended 2022-03-31 |